New Biodecontamination Range Complements Cherwells Sterilisation Process Validation Products
The importance of efficient, reliable decontamination of cleanrooms and other critical areas within the healthcare, pharmaceutical and biotech industries is undeniable. Having signed a UK distribution agreement with Mar Cor Purification, Cherwell Laboratories can now offer a range of dry fog technology and cold sterilant products to provide the ideal solution.
The addition of Mar Cor Purification’s decontamination products complements the existing product portfolio enabling Cherwell to offer a comprehensive solution to customers. The new decontamination range, suitable for use in pharmaceutical cleanrooms and other critical areas, incorporates the highly effective Minncare Dry Fog and Mini Dry Fog systems plus Minncare and Actril Cold Sterilants.
Alongside the new decontamination range, Cherwell offers biological indicators for the validation of sterilisation processes, Redipor prepared microbiological media and SAS microbial air samplers. The range has been developed over time to meet the changing regulations within the pharmaceutical and related industries whilst maintaining Cherwell’s commitment to offering the highest quality products, expert advice and customer service levels.
“We are very excited to enter a UK distribution agreement with Mar Cor Purification,” said Andy Whittard, Managing Director, Cherwell Laboratories. “The Dry Fog and cold sterilant decontamination products provide an ideal synergy with Cherwell’s current product range, and meet our high expectations for product quality and customer service.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.